DK1285080T3 - Fremgangsmåde til oprensning af alphavirusreplikonpartikler - Google Patents
Fremgangsmåde til oprensning af alphavirusreplikonpartiklerInfo
- Publication number
- DK1285080T3 DK1285080T3 DK01941874T DK01941874T DK1285080T3 DK 1285080 T3 DK1285080 T3 DK 1285080T3 DK 01941874 T DK01941874 T DK 01941874T DK 01941874 T DK01941874 T DK 01941874T DK 1285080 T3 DK1285080 T3 DK 1285080T3
- Authority
- DK
- Denmark
- Prior art keywords
- purification
- alphavirus replicon
- methods
- replicon particles
- disclosed
- Prior art date
Links
- 241000710929 Alphavirus Species 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 239000002245 particle Substances 0.000 title abstract 3
- 238000000746 purification Methods 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 abstract 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 abstract 1
- 238000011097 chromatography purification Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003456 ion exchange resin Substances 0.000 abstract 1
- 229920003303 ion-exchange polymer Polymers 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36151—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Powder Metallurgy (AREA)
- Disintegrating Or Milling (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20837600P | 2000-05-31 | 2000-05-31 | |
PCT/US2001/018021 WO2001092552A2 (en) | 2000-05-31 | 2001-05-31 | Method for the purification of alphavirus replicon particles |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1285080T3 true DK1285080T3 (da) | 2008-12-01 |
Family
ID=22774372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01941874T DK1285080T3 (da) | 2000-05-31 | 2001-05-31 | Fremgangsmåde til oprensning af alphavirusreplikonpartikler |
Country Status (9)
Country | Link |
---|---|
US (4) | US6767699B2 (da) |
EP (1) | EP1285080B1 (da) |
AT (1) | ATE409749T1 (da) |
AU (1) | AU2001275191A1 (da) |
CA (1) | CA2410948C (da) |
DE (1) | DE60135983D1 (da) |
DK (1) | DK1285080T3 (da) |
ES (1) | ES2312447T3 (da) |
WO (1) | WO2001092552A2 (da) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
AU2002303330B2 (en) | 2001-05-31 | 2008-07-24 | Novartis Vaccines And Diagnostics, Inc. | Chimeric alphavirus replicon particles |
JP4790984B2 (ja) * | 2001-09-06 | 2011-10-12 | アルファヴァックス,インコーポレイテッド | アルファウイルスレプリコンベクター系 |
US7195905B2 (en) * | 2001-12-10 | 2007-03-27 | Baxter Healthcare S.A. | Enveloped virus vaccine and method for production |
ATE427990T1 (de) | 2002-04-30 | 2009-04-15 | Oncolytics Biotech Inc | Verbesserte reinigungsmethode fur viren |
WO2004030631A2 (en) | 2002-10-01 | 2004-04-15 | Chiron Corporation | Anti-cancer and anti-infectious disease compositions and methods for using same |
ES2618309T3 (es) | 2002-12-13 | 2017-06-21 | Alphavax, Inc. | Partículas de replicón de alfavirus multi-antigénico y métodos |
DK2290054T3 (da) * | 2002-12-13 | 2017-07-03 | Alphavax Inc | Alfavirus-partikler og fremgangsmåder til fremstilling deraf |
KR101454842B1 (ko) * | 2003-03-20 | 2014-11-04 | 알파벡스, 인크. | 개선된 알파바이러스 레플리콘 및 헬퍼 구축물 |
US7419674B2 (en) * | 2003-07-11 | 2008-09-02 | Alpha Vax, Inc. | Alpha virus-based cytomegalovirus vaccines |
CA2567254C (en) * | 2004-05-18 | 2012-03-13 | Alphavax, Inc. | Tc-83-derived alphavirus vectors, particles and methods |
JP4896021B2 (ja) | 2004-05-21 | 2012-03-14 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | 呼吸器系病原体ワクチンのためのアルファウイルスベクター |
US7901921B2 (en) * | 2004-10-22 | 2011-03-08 | Oncolytics Biotech Inc. | Viral purification methods |
EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
KR100760525B1 (ko) * | 2006-04-13 | 2007-10-04 | 김재만 | 병원성 미생물의 무증폭 다중 정량 검출킷트 및 검출방법 |
EP2061508B1 (en) * | 2006-09-12 | 2014-10-15 | Alphavax, Inc. | Alphavirus replicon particles matched to protein antigens as immunological adjuvants |
WO2008085557A2 (en) | 2006-09-12 | 2008-07-17 | Alphavax, Inc. | Alphavirus replicon particles encoding il- 12 as immunological adjuvants |
DK2099485T3 (da) * | 2006-11-03 | 2018-05-22 | Alphavax Inc | Alfavirus- og alfavirusreplikonpartikelformuleringer samt tilhørende fremgangsmåder |
AU2008266807B2 (en) * | 2007-06-21 | 2012-08-16 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
US8680258B2 (en) | 2008-12-01 | 2014-03-25 | Alphavax, Inc. | Use of microRNAs to control virus helper nucleic acids |
CN105056229A (zh) | 2009-01-05 | 2015-11-18 | 埃皮托吉尼西斯股份有限公司 | 佐剂组合物及使用方法 |
US10072307B1 (en) | 2009-01-23 | 2018-09-11 | Colorado State University Research Foundation | Isolation of viruses using anionic resin beads |
AU2010234362B2 (en) | 2009-04-08 | 2015-11-26 | Alphavax, Inc. | Alphavirus replicon particles expressing TRP2 |
KR20150023923A (ko) | 2010-07-30 | 2015-03-05 | 이엠디 밀리포어 코포레이션 | 크로마토그래피 매질 및 방법 |
US8895291B2 (en) | 2010-10-08 | 2014-11-25 | Terumo Bct, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
US10561720B2 (en) | 2011-06-24 | 2020-02-18 | EpitoGenesis, Inc. | Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators |
CN105992816B (zh) | 2013-11-16 | 2018-04-17 | 泰尔茂比司特公司 | 生物反应器中的细胞扩增 |
EP3613841B1 (en) | 2014-03-25 | 2022-04-20 | Terumo BCT, Inc. | Passive replacement of media |
CN106794389A (zh) | 2014-09-02 | 2017-05-31 | Emd密理博公司 | 具有纳米原纤化表面特征的高表面积纤维介质 |
JP6830059B2 (ja) | 2014-09-26 | 2021-02-17 | テルモ ビーシーティー、インコーポレーテッド | スケジュール化された細胞フィーディング |
SG11201703399QA (en) | 2014-12-08 | 2017-05-30 | Emd Millipore Corp | Mixed bed ion exchange adsorber |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
EP3393507B1 (en) | 2015-12-23 | 2024-02-07 | Valneva Austria GmbH | Zika virus purification |
WO2017205667A1 (en) | 2016-05-25 | 2017-11-30 | Terumo Bct, Inc. | Cell expansion |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
CN117247899A (zh) | 2017-03-31 | 2023-12-19 | 泰尔茂比司特公司 | 细胞扩增 |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
NZ761619A (en) | 2017-09-21 | 2024-03-22 | Valneva Se | Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3 |
NL2022538B1 (en) | 2019-02-08 | 2020-08-19 | Academisch Ziekenhuis Groningen | Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof. |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5466788A (en) * | 1985-03-07 | 1995-11-14 | Mycogen Plant Science, Inc. | Subgenomic promoter |
ES8800988A1 (es) | 1985-04-05 | 1987-12-16 | Meloy Lab | Procedimiento de producir interferona humana. |
US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
WO1988000472A1 (en) | 1986-07-23 | 1988-01-28 | Aphton Corporation | Immunogens and improved methods of making immunogens |
US5716826A (en) | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
US5093239A (en) | 1988-05-02 | 1992-03-03 | Eastman Kodak Company | Reagents for detecting oxidase positive microorganisms |
US5614404A (en) | 1988-06-10 | 1997-03-25 | Theriod Biologics, Incorporated | Self-assembled, defective, non-self-propagating lentivirus particles |
US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
US5026686A (en) | 1989-02-01 | 1991-06-25 | Washington University | Antiviral peptides |
US5185440A (en) | 1989-06-20 | 1993-02-09 | North Carolina State University | cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof |
EP0487587A1 (en) | 1989-08-18 | 1992-06-03 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
JPH06502311A (ja) | 1990-10-22 | 1994-03-17 | フォックス・チェイス・キャンサー・センター | Rna療法を提供するためのdna構造 |
SE9003978D0 (sv) | 1990-12-13 | 1990-12-13 | Henrik Garoff | Dna expressionssystem baserade paa ett virus replikon |
US5279823A (en) | 1992-06-08 | 1994-01-18 | Genentech, Inc. | Purified forms of DNASE |
WO1994017813A1 (en) | 1993-02-08 | 1994-08-18 | Paravax, Inc. | Defective sindbis virus vectors that express toxoplasma gondii p30 antigens |
DE4315109A1 (de) | 1993-05-06 | 1994-11-10 | Inst Pflanzengenetik & Kultur | Verfahren und Vektorkonstrukt zur Expressionssteigerung von Transgenen |
EP0647716B1 (fr) | 1993-07-06 | 2003-09-24 | Universite De Nice-Sophia Antipolis | Vecteur comportant un gène viral transcrit par l'ARN polymérase III |
US5837503A (en) | 1993-07-07 | 1998-11-17 | Universite De Nice-Sophia-Antipolis | Vector containing viral gene transcribed by RNA polymerase III and methods for use |
EP0716148B1 (en) | 1993-09-15 | 2004-01-02 | Chiron Corporation | Recombinant alphavirus vectors |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
US5591579A (en) | 1993-12-21 | 1997-01-07 | Washington University | Indicator cell line for detecting RNA viruses and method therefor |
IL112371A0 (en) | 1994-01-25 | 1995-03-30 | Res Dev Foundation | A novel protein from aedes albopictus cells and methods for its use |
US5498537A (en) * | 1994-03-09 | 1996-03-12 | Cellco, Inc. | Serum-free production of packaged viral vector |
US5532154A (en) | 1994-03-21 | 1996-07-02 | Research Development Foundation | Mutated alpha virus |
SE9401091D0 (sv) | 1994-03-31 | 1994-03-31 | Bioption Ab | Alphavirus cDNA vectors |
GB9406498D0 (en) | 1994-03-31 | 1994-05-25 | Smithkline Beecham Biolog | Novel compounds |
SE9401709D0 (sv) | 1994-05-18 | 1994-05-18 | Mathilda Sjoeberg | Improved alphavirus vectors for expression of heterologous DNA |
US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
US5837520A (en) * | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
US5797870A (en) | 1995-06-07 | 1998-08-25 | Indiana University Foundation | Pericardial delivery of therapeutic and diagnostic agents |
EP0847442A1 (en) | 1995-08-30 | 1998-06-17 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
WO1997016169A1 (en) | 1995-11-01 | 1997-05-09 | Chiron Corporation | Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space |
WO1997024447A1 (en) | 1996-01-02 | 1997-07-10 | Chiron Corporation | Immunostimulation mediated by gene-modified dendritic cells |
AU2051297A (en) | 1996-02-15 | 1997-09-02 | Chiron Corporation | Gene therapy method using fgf-5 |
US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
WO1997038087A2 (en) | 1996-04-05 | 1997-10-16 | Chiron Corporation | Alphaviral vector with reduced inhibition of cellular macromolecular synthesis |
AU3210997A (en) | 1996-05-24 | 1997-12-09 | University Of Maryland At Baltimore | Dna vaccines for eliciting a mucosal immune response |
US5843712A (en) | 1996-06-06 | 1998-12-01 | The Trustees Of Columbia University In The City Of New York | Sindbis virus expression system for recombinant antibody production |
WO1998013511A1 (en) | 1996-09-25 | 1998-04-02 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic togavirus vectors |
EP0932693A1 (en) | 1996-10-10 | 1999-08-04 | Henrik Garoff | Alphavirus-retrovirus vectors |
AU7637796A (en) | 1996-12-09 | 1998-07-03 | James Edwin Bailey | Expression of active interferon beta 1 using recombinant rna replicons |
US6261823B1 (en) * | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
US5811407A (en) * | 1997-02-19 | 1998-09-22 | The University Of North Carolina At Chapel Hill | System for the in vivo delivery and expression of heterologous genes in the bone marrow |
US6261570B1 (en) | 1997-05-20 | 2001-07-17 | The United States Of America As Represented By The Secretary Of The Army | Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants |
EP0996737A1 (en) | 1997-08-15 | 2000-05-03 | Inex Pharmaceuticals Corp. | Semliki forest virus vectors for gene transfer into non-endothelial cardiovascular cells |
US6060308A (en) | 1997-09-04 | 2000-05-09 | Connaught Laboratories Limited | RNA respiratory syncytial virus vaccines |
JP2001517433A (ja) | 1997-09-24 | 2001-10-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 非霊長類レンチウイルスベクターおよびパッケージングシステム |
EP1034289A1 (en) | 1997-11-14 | 2000-09-13 | Connaught Laboratories Limited | Alphavirus vectors for paramyxovirus vaccines |
WO1999025859A1 (en) | 1997-11-14 | 1999-05-27 | Connaught Laboratories Limited | Alphavirus vectors |
WO1999030734A1 (en) | 1997-12-18 | 1999-06-24 | G.D. Searle & Co. | Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity |
-
2001
- 2001-05-31 DK DK01941874T patent/DK1285080T3/da active
- 2001-05-31 ES ES01941874T patent/ES2312447T3/es not_active Expired - Lifetime
- 2001-05-31 AT AT01941874T patent/ATE409749T1/de active
- 2001-05-31 DE DE60135983T patent/DE60135983D1/de not_active Expired - Lifetime
- 2001-05-31 AU AU2001275191A patent/AU2001275191A1/en not_active Abandoned
- 2001-05-31 US US09/872,086 patent/US6767699B2/en not_active Expired - Fee Related
- 2001-05-31 CA CA2410948A patent/CA2410948C/en not_active Expired - Fee Related
- 2001-05-31 WO PCT/US2001/018021 patent/WO2001092552A2/en active Application Filing
- 2001-05-31 EP EP01941874A patent/EP1285080B1/en not_active Expired - Lifetime
-
2004
- 2004-06-29 US US10/881,575 patent/US20050112752A1/en not_active Abandoned
-
2008
- 2008-09-18 US US12/212,978 patent/US20100055128A1/en not_active Abandoned
-
2012
- 2012-03-27 US US13/430,920 patent/US20120231526A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2001275191A1 (en) | 2001-12-11 |
WO2001092552A3 (en) | 2002-05-23 |
ES2312447T3 (es) | 2009-03-01 |
US6767699B2 (en) | 2004-07-27 |
DE60135983D1 (de) | 2008-11-13 |
CA2410948A1 (en) | 2001-12-06 |
WO2001092552A2 (en) | 2001-12-06 |
US20020015945A1 (en) | 2002-02-07 |
US20050112752A1 (en) | 2005-05-26 |
EP1285080A2 (en) | 2003-02-26 |
US20120231526A1 (en) | 2012-09-13 |
EP1285080B1 (en) | 2008-10-01 |
CA2410948C (en) | 2012-07-17 |
ATE409749T1 (de) | 2008-10-15 |
US20100055128A1 (en) | 2010-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1285080T3 (da) | Fremgangsmåde til oprensning af alphavirusreplikonpartikler | |
ATE472335T1 (de) | Chimere alphavirus-replikon-partikel | |
ATE420965T1 (de) | Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren | |
MX2019000252A (es) | Administracion viral oncolitica pseudotipada de polipeptidos terapeuticos. | |
DK1651666T3 (da) | Alfavirus-baserede cytomegalovirusvacciner | |
FI932678A0 (fi) | Pao alfavirus baserande DNA expressionssystem | |
NO964862L (no) | Papillomavirusvaksiner | |
DK1519944T3 (da) | Fremgangsmåder til fremstilling af fibrinogen | |
CR20210370A (es) | Neoantígenos prostáticos y sus usos | |
MX2022014161A (es) | Vacunas contra sars-cov-2. | |
BRPI0516576A (pt) | vetores quiméricos | |
WO2007046839A3 (en) | New live virus vaccines | |
WO2001021807A8 (en) | Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof | |
ATE404582T1 (de) | Immunogene zusammensetzungen, die replikonvektoren des venezolanischen pferdeencephalitisvirus und paramyxovirus- proteinantigene enthalten | |
ATE321853T1 (de) | Humanische pellino-polypeptide | |
MX2007002659A (es) | Composicion vacunal contra el virus de la hepatitis c. | |
WO2003072725A3 (en) | Recombinant negative strand virus rna expression systems and vaccines | |
DE60040219D1 (de) | Infektiöses cdna klon des gb-virus b und dessen verwendungen | |
WO2008027560A3 (en) | Holin-enhanced vaccines and reagents, and methods of use thereof | |
DK1423525T3 (da) | Rekombinant MVA, der kan eksprimere HCV-strukturantigener | |
Lampe et al. | Anomalous transport coefficients for HANE applications due to plasma micro-instabilities | |
YU16292A (sh) | Novi etnomopoksvirusni ekspresioni sistem | |
ATE318893T1 (de) | Verbesserte replikation von hcv rna | |
DK1594991T3 (da) | Fremgangsmåde til fremstilling af DNA-molekyler | |
ATE263234T1 (de) | Veränderte, kleine rna-viren |